Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Labor Stage, First Clear all
Recruiting Not applicable Interventional

Maternal Maneuvers During Prolonged Labor

NCT06636149
View directory record Official record
Conditions
Labor Stage, First, Prolonged Labor
Interventions
Circuit of maternal position changes during labor
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Saint Loius, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic

NCT07693751
View directory record Official record
Conditions
Colorectal Cancer (Locally Advanced or Metastatic)
Interventions
SOT109
Biological
Lead sponsor
SOTIO Biotech a.s.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Houston, Texas • Faifax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions
Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Newport Beach, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Analgesic Techniques on Duration of Spontaneously Laboring Patients

NCT01982838
View directory record Official record
Conditions
Effects of; Anesthesia, in Labor and Delivery, Pregnancy, Prolonged First Stage of Labor
Interventions
Epidural de novo, CSE
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Jul 23, 2026, 11:06 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT04626635
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

NCT07392255
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
CTx001
Genetic
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Maternal Positioning to Correct Fetal Occiput Posterior

NCT05307393
View directory record Official record
Conditions
Obstetric Complication
Interventions
Positioning
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jul 23, 2026, 11:06 PM EDT
Recruiting Phase 1 Interventional

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
BAY 3547926, BAY 3547922, BAY 3713391, BAY 3713389
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Dothan, Alabama • Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

NCT06413680
View directory record Official record
Conditions
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Interventions
REGN10597, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Recruiting Phase 3 Interventional

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions
Sigvotatug Vedotin, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
75
States / cities
Fullerton, California • Golden, Colorado • Grand Junction, Colorado + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 11:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Analgesic Techniques on Duration of Labor for Induction Patients

NCT01982851
View directory record Official record
Conditions
Effects of; Anesthesia, in Labor and Delivery, Pregnancy, Prolonged First Stage of Labor
Interventions
Epidural de novo, CSE
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Jul 23, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

NCT04147819
View directory record Official record
Conditions
Cancers With HER2 Expression
Interventions
BAY2701439
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 23, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment

NCT01410110
View directory record Official record
Conditions
Substance Abuse, Substance Dependence, Cognitive Impairment
Interventions
Cognitive Training + Work Therapy, Work Therapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jul 23, 2026, 11:06 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
29
States / cities
Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 11:06 PM EDT